This partnership is a platform validation event, not a revenue event. It strengthens Alamar's positioning in the neurodegenerative proteomics market but provides no near-term financial catalyst. Monitor for future commercial contracts or diagnostic kit sales that may follow from this academic validation.
Price Chart
Executive Summary
Alamar Biosciences announced a partnership with leading research universities to profile ~21,000 plasma samples from 10,000 Alzheimer's Disease Research Center participants using its NULISAseq Neuro 220 panel. The initiative is part of the CLARiTI portfolio and will create a publicly accessible proteomic dataset linked to NACC IDs, supporting biomarker discovery and AI-driven analysis. This is a non-revenue-generating research collaboration that validates Alamar's platform in a large-scale academic setting but does not provide near-term financial impact.
Key Facts
- Partnership with Washington University, University of Wisconsin, and Indiana University to profile ~21,000 plasma samples from 10,000 ADRD participants
- Uses Alamar's NULISAseq Neuro 220 panel with newly added eMTBR-Tau assay for tau tangle burden measurement
- Project is part of the CLARiTI portfolio, leveraging infrastructure from Alzheimer's Association, Robertson Foundation, and an anonymous foundation
- All data will be made freely available to the global research community, linked to NACC IDs for multimodal analysis
- Next phase includes a national data challenge for AI-driven biomarker discovery
Financial Impact
No financial terms disclosed; this is a non-revenue-generating research collaboration that validates Alamar's platform in a large-scale academic setting
Risk Factors
- No financial terms disclosed — this is a non-revenue-generating academic collaboration
- Data will be made publicly available, limiting Alamar's ability to monetize the dataset directly
- Project depends on sustained academic and philanthropic partnerships
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3325909 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.81 (−12.36%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.81 (−12.36%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.81 (+12.36%) |
Oct 5, 2026 21d ago | Press Release | $32.26 | awaiting T+60 | — | $30.81 (−4.49%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $30.81 (−6.07%) |
Sep 1, 2026 7w ago | 8-K | $30.49 | awaiting T+60 | — | $30.81 (+1.05%) |
Aug 10, 2026 11w ago | 8-K | $36.57 | awaiting T+60 | — | $30.81 (−15.75%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $30.81 (+12.45%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $30.81 (+8.41%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $30.81 (+28.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers